Brief: Ironwood Pharmaceuticals Announces Positive Topline Results From Global Phase III Trial Of Once-Weekly Apraglutide In Adults

Ironwood Pharmaceuticals

29/02/2024 11:01

Feb 29 (Reuters) - Ironwood Pharmaceuticals Inc
 IRWD.O :
    * IRONWOOD PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE
RESULTS FROM
GLOBAL PHASE III TRIAL OF ONCE-WEEKLY APRAGLUTIDE IN ADULTS WITH
SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF)
    * IRONWOOD PHARMACEUTICALS - APRAGLUTIDE SHOWED CLINICALLY
MEANINGFUL IMPROVEMENT AT WEEK 24, WITH PATIENTS ACHIEVING AT
LEAST ONE DAY OFF PS PER WEEK
    * IRONWOOD PHARMACEUTICALS- APRAGLUTIDE MET PRIMARY ENDPOINT
OF
RELATIVE CHANGE FROM BASELINE IN ACTUAL WEEKLY PARENTERAL
SUPPORT (PS) VOLUME AT WEEK 24
    * IRONWOOD PHARMACEUTICALS INC - TO SUBMIT NEW DRUG
APPLICATION
AND OTHER REGULATORY FILINGS FOR APRAGLUTIDE AS A ONCE-WEEKLY
GLP-2 ANALOG
    * IRONWOOD PHARMACEUTICALS INC - APRAGLUTIDE WAS GENERALLY
WELL-TOLERATED,
    * IRONWOOD PHARMACEUTICALS INC - TOPLINE SAFETY RESULTS WERE
GENERALLY CONSISTENT WITH SAFETY PROFILE DEMONSTRATED IN
APRAGLUTIDE STUDIES TO DATE
    * IRONWOOD PHARMACEUTICALS INC - SAFETY PROFILE WAS
CONSISTENT
WITH PREVIOUSLY-REPORTED STUDIES OF APRAGLUTIDE IN THIS PATIENT
POPULATION

Source text for Eikon:  ID:nBw9wBSTVa 
Further company coverage:  IRWD.O 

 ((Reuters.Briefs@thomsonreuters.com;))